Table 3 Demographics and clinical background of participants (N = 1080)
Variable | Patients with ADR (n = 217) | Patients without ADR (n = 863) | P value |
|---|---|---|---|
Age (mean ± SD in years) | 47.96 ± 16.50 | 40.07 ± 16.51 | < 0.001†|
Sex | |||
   Male | 137 (63.1%) | 593 (68.7%) | 0.116‡ |
    Female | 80 (36.9%) | 270 (31.3%) |  |
History of drug allergy | |||
    Yes | 5 (2.3%) | 26 (3.0%) | 0.576‡ |
    No | 212 (97.7%) | 837 (97.0%) |  |
Presence of comorbidity | |||
    Yes | 117 (53.9%) | 294 (34.1%) | < 0.001‡ |
    No | 100 (46.1%) | 569 (65.9%) |  |
COVID-19 category | |||
    Patient under investigation | 9 (4.1%) | 80 (9.3%) |  |
    Stage 1 | 1 (0.5%) | 35 (4.1%) |  |
    Stage 2 | 27 (12.4%) | 357 (41.4%) |  |
    Stage 3 | 85 (39.1%) | 311 (36.0%) |  |
    Stage 4 | 79 (36.4%) | 58 (6.7%) |  |
    Stage 5 | 16 (7.4%) | 22 (2.5%) |  |
Number of COVID-19 drug(s) | |||
    1 | 51 (23.5%) | 704 (81.6%) |  |
    2 | 96 (44.2%) | 115 (13.3%) |  |
    3 | 46 (21.2%) | 30 (3.5%) |  |
    4 and 5 | 24 (11.1%) | 14 (1.6%) |  |